請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/8968
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林思洸 | |
dc.contributor.author | Kou-Liang Hou | en |
dc.contributor.author | 侯國亮 | zh_TW |
dc.date.accessioned | 2021-05-20T20:05:21Z | - |
dc.date.available | 2011-09-15 | |
dc.date.available | 2021-05-20T20:05:21Z | - |
dc.date.copyright | 2009-09-15 | |
dc.date.issued | 2009 | |
dc.date.submitted | 2009-08-14 | |
dc.identifier.citation | 1 Haas, C. S., Creighton, C. J., Pi, X., Maine, I., Koch, A. E., Haines, G. K., Ling,
S., Chinnaiyan, A. M., and Holoshitz, J., Identification of genes modulated in rheumatoid arthritis using complementary DNA microarray analysis of lymphoblastoid B cell lines from disease-discordant monozygotic twins. Arthritis Rheum 54 (7), 2047 (2006). 2 Radke, S., Battmann, A., Jatzke, S., Eulert, J., Jakob, F., and Schutze, N., Expression of the angiomatrix and angiogenic proteins CYR61, CTGF, and VEGF in osteonecrosis of the femoral head. J Orthop Res 24 (5), 945 (2006). 3 Kunz, M., Moeller, S., Koczan, D., Lorenz, P., Wenger, R. H., Glocker, M. O., Thiesen, H. J., Gross, G., and Ibrahim, S. M., Mechanisms of hypoxic gene regulation of angiogenesis factor Cyr61 in melanoma cells. J Biol Chem 278 (46), 45651 (2003). 4 O'Brien, T. P., Yang, G. P., Sanders, L., and Lau, L. F., Expression of cyr61, a growth factor-inducible immediate-early gene. Mol Cell Biol 10 (7), 3569 (1990). 5 Brigstock, D. R., The CCN family: a new stimulus package. J Endocrinol 178 (2), 169 (2003). 6 Yang, G. P. and Lau, L. F., Cyr61, product of a growth factor-inducible immediate early gene, is associated with the extracellular matrix and the cell surface. Cell Growth Differ 2 (7), 351 (1991). 7 Moritani, N. H., Kubota, S., Sugahara, T., and Takigawa, M., Comparable response of ccn1 with ccn2 genes upon arthritis: An in vitro evaluation with a human chondrocytic cell line stimulated by a set of cytokines. Cell Commun Signal 3 (1), 6 (2005). 47 8 Rooney, M., Condell, D., Quinlan, W., Daly, L., Whelan, A., Feighery, C., and Bresnihan, B., Analysis of the histologic variation of synovitis in rheumatoid arthritis. Arthritis Rheum 31 (8), 956 (1988). 9 Lund-Olesen, K., Oxygen tension in synovial fluids. Arthritis Rheum 13 (6), 769 (1970); Paleolog, E. M., Angiogenesis in rheumatoid arthritis. Arthritis Res 4 Suppl 3, S81 (2002). 10 Jawed, S., Gaffney, K., and Blake, D. R., Intra-articular pressure profile of the knee joint in a spectrum of inflammatory arthropathies. Ann Rheum Dis 56 (11), 686 (1997). 11 Brown, R. A., Weiss, J. B., Tomlinson, I. W., Phillips, P., and Kumar, S., Angiogenic factor from synovial fluid resembling that from tumours. Lancet 1 (8170), 682 (1980). 12 Semble, E. L., Turner, R. A., and McCrickard, E. L., Rheumatoid arthritis and osteoarthritis synovial fluid effects on primary human endothelial cell cultures. J Rheumatol 12 (2), 237 (1985). 13 Zhou, D., Herrick, D. J., Rosenbloom, J., and Chaqour, B., Cyr61 mediates the expression of VEGF, alphav-integrin, and alpha-actin genes through cytoskeletally based mechanotransduction mechanisms in bladder smooth muscle cells. J Appl Physiol 98 (6), 2344 (2005). 14 Goldstein, J. L. and Brown, M. S., Regulation of the mevalonate pathway. Nature 343 (6257), 425 (1990). 15 Matar, P., Rozados, V. R., Roggero, E. A., and Scharovsky, O. G., Lovastatin inhibits tumor growth and metastasis development of a rat fibrosarcoma. Cancer Biother Radiopharm 13 (5), 387 (1998). 16 Kureishi, Y., Luo, Z., Shiojima, I., Bialik, A., Fulton, D., Lefer, D. J., Sessa, W. 48 C., and Walsh, K., The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6 (9), 1004 (2000). 17 Fassbender, K., Simons, M., Bergmann, C., Stroick, M., Lutjohann, D., Keller, P., Runz, H., Kuhl, S., Bertsch, T., von Bergmann, K., Hennerici, M., Beyreuther, K., and Hartmann, T., Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A 98 (10), 5856 (2001). 18 Kwak, B., Mulhaupt, F., Myit, S., and Mach, F., Statins as a newly recognized type of immunomodulator. Nat Med 6 (12), 1399 (2000). 19 Ho, M. L., Chen, Y. H., Liao, H. J., Chen, C. H., Hung, S. H., Lee, M. J., Fu, Y. C., Wang, Y. H., Wang, G. J., and Chang, J. K., Simvastatin increases osteoblasts and osteogenic proteins in ovariectomized rats. Eur J Clin Invest 39 (4), 296 (2009). 20 LaCroix, A. Z., Cauley, J. A., Pettinger, M., Hsia, J., Bauer, D. C., McGowan, J., Chen, Z., Lewis, C. E., McNeeley, S. G., Passaro, M. D., and Jackson, R. D., Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Ann Intern Med 139 (2), 97 (2003); Bjarnason, N. H., Riis, B. J., and Christiansen, C., The effect of fluvastatin on parameters of bone remodeling. Osteoporos Int 12 (5), 380 (2001); von Stechow, D., Fish, S., Yahalom, D., Bab, I., Chorev, M., Muller, R., and Alexander, J. M., Does simvastatin stimulate bone formation in vivo? BMC Musculoskelet Disord 4, 8 (2003). 21 Tang, Q. O., Tran, G. T., Gamie, Z., Graham, S., Tsialogiannis, E., Tsiridis, E., and Linder, T., Statins: under investigation for increasing bone mineral density 49 and augmenting fracture healing. Expert Opin Investig Drugs 17 (10), 1435 (2008). 22 Essaghir, A., Dif, N., Marbehant, C. Y., Coffer, P. J., and Demoulin, J. B., The transcription of FOXO genes is stimulated by FOXO3 and repressed by growth factors. J Biol Chem 284 (16), 10334 (2009). 23 Huang, H. and Tindall, D. J., Dynamic FoxO transcription factors. J Cell Sci 120 (Pt 15), 2479 (2007). 24 Lee, H. Y., Chung, J. W., Youn, S. W., Kim, J. Y., Park, K. W., Koo, B. K., Oh, B. H., Park, Y. B., Chaqour, B., Walsh, K., and Kim, H. S., Forkhead transcription factor FOXO3a is a negative regulator of angiogenic immediate early gene CYR61, leading to inhibition of vascular smooth muscle cell proliferation and neointimal hyperplasia. Circ Res 100 (3), 372 (2007). 25 Inoue, T., Hiratsuka, M., Osaki, M., and Oshimura, M., The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation. Cell Cycle 6 (9), 1011 (2007). 26 Salminen, A. and Kaarniranta, K., SIRT1: Regulation of longevity via autophagy. Cell Signal (2009). 27 Frescas, D., Valenti, L., and Accili, D., Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. J Biol Chem 280 (21), 20589 (2005). 28 Estrada, R., Li, N., Sarojini, H., An, J., Lee, M. J., and Wang, E., Secretome from mesenchymal stem cells induces angiogenesis via Cyr61. J Cell Physiol 219 (3), 563 (2009). 29 Juric, V., Chen, C. C., and Lau, L. F., Fas-Mediated Apoptosis is Regulated by the Extracellular Matrix Protein CCN1 (CYR61) in vitro and in vivo. Mol Cell 50 Biol (2009). 30 Matsuzaki, H., Daitoku, H., Hatta, M., Aoyama, H., Yoshimochi, K., and Fukamizu, A., Acetylation of Foxo1 alters its DNA-binding ability and sensitivity to phosphorylation. Proc Natl Acad Sci U S A 102 (32), 11278 (2005). 31 Kim, M. J., Ahn, K., Park, S. H., Kang, H. J., Jang, B. G., Oh, S. J., Oh, S. M., Jeong, Y. J., Heo, J. I., Suh, J. G., Lim, S. S., Ko, Y. J., Huh, S. O., Kim, S. C., Park, J. B., Kim, J., Kim, J. I., Jo, S. A., and Lee, J. Y., SIRT1 regulates tyrosine hydroxylase expression and differentiation of neuroblastoma cells via FOXO3a. FEBS Lett 583 (7), 1183 (2009). 32 Giannakou, M. E. and Partridge, L., The interaction between FOXO and SIRT1: tipping the balance towards survival. Trends Cell Biol 14 (8), 408 (2004). 33 Bansback, N., Ara, R., Ward, S., Anis, A., and Choi, H. K., Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis. Pharmacoeconomics 27 (1), 25 (2009). 34 Paraskevas, K. I., Statin treatment for rheumatoid arthritis: a promising novel indication. Clin Rheumatol 27 (3), 281 (2008). 35 Calnan, D. R. and Brunet, A., The FoxO code. Oncogene 27 (16), 2276 (2008). 36 Yamagata, K., Daitoku, H., Takahashi, Y., Namiki, K., Hisatake, K., Kako, K., Mukai, H., Kasuya, Y., and Fukamizu, A., Arginine methylation of FOXO transcription factors inhibits their phosphorylation by Akt. Mol Cell 32 (2), 221 (2008). 37 Gomis, R. R., Alarcon, C., He, W., Wang, Q., Seoane, J., Lash, A., and Massague, J., A FoxO-Smad synexpression group in human keratinocytes. Proc Natl Acad Sci U S A 103 (34), 12747 (2006). 38 van der Heide, L. P. and Smidt, M. P., Regulation of FoxO activity by 51 CBP/p300-mediated acetylation. Trends Biochem Sci 30 (2), 81 (2005). 39 Salminen, A., Ojala, J., Huuskonen, J., Kauppinen, A., Suuronen, T., and Kaarniranta, K., Interaction of aging-associated signaling cascades: inhibition of NF-kappaB signaling by longevity factors FoxOs and SIRT1. Cell Mol Life Sci 65 (7-8), 1049 (2008). 40 Kobayashi, Y., Furukawa-Hibi, Y., Chen, C., Horio, Y., Isobe, K., Ikeda, K., and Motoyama, N., SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress. Int J Mol Med 16 (2), 237 (2005). 41 Zhao, W., Kruse, J. P., Tang, Y., Jung, S. Y., Qin, J., and Gu, W., Negative regulation of the deacetylase SIRT1 by DBC1. Nature 451 (7178), 587 (2008). 42 Onuma, H., Vander Kooi, B. T., Boustead, J. N., Oeser, J. K., and O'Brien, R. M., Correlation between FOXO1a (FKHR) and FOXO3a (FKHRL1) binding and the inhibition of basal glucose-6-phosphatase catalytic subunit gene transcription by insulin. Mol Endocrinol 20 (11), 2831 (2006). 43 Alam, S., Ueki, K., Nakagawa, K., Marukawa, K., Hashiba, Y., Yamamoto, E., Sakulsak, N., and Iseki, S., Statin-induced bone morphogenetic protein (BMP) 2 expression during bone regeneration: an immunohistochemical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 107 (1), 22 (2009). 44 Giampietro, P. F., McCarty, C., Mukesh, B., McKiernan, F., Wilson, D., Shuldiner, A., Liu, J., Levasseur, J., Ivacic, L., Kitchner, T., and Ghebranious, N., The role of cigarette smoking and statins in the development of postmenopausal osteoporosis: a pilot study utilizing the Marshfield Clinic Personalized Medicine Cohort. Osteoporos Int (2009). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/8968 | - |
dc.description.abstract | 類風濕性關節炎(Rheumatoid arthritis,RA)是由於人體產生自體免疫導致在關節處產生慢性發炎所造成的現象。關節處不斷的發炎反應會導致滑膜組織(synovial tissue)不斷的增生,逐漸增大向其他位置侵襲,造成骨頭的損失。另外慢性發炎反應的持續進行,也會吸引巨噬細胞等免疫細胞浸潤達發炎處,促進蝕骨細胞(osteoclasts)的形成,進行骨吸收的作用。目前對於其詳細的研究機制則仍待更進一步的探討。
Cyr61 ( Cysteine- rich angiogenic inducer 61),CCN家族成員之一,目前已知在細胞生長、血管新生、腫瘤生長、發炎反應等等有關,相關文獻發現在關節炎患者中的B細胞中,Cyr61會不正常的大量表現,且Cyr61也會促進血管新生以及巨噬細胞的吸引,因此Cyr61在關節炎中可能扮演一個重要的角色。有鑒於關節炎的致病機制還不清楚,我們希望能夠透過了解Cyr61在關節炎中扮演的地位,在治療此疾病上能夠提供更有力的方法。 我們初步的研究顯示,在Collagen-Induced Arthritis(CIA)的大鼠模式中,發現受侵蝕的骨頭周圍有大量Cyr61的表現。此大量表現Cyr61蛋白質的位置恰好符合巨噬細胞的所在,初步推論Cyr61蛋白質可以吸引巨噬細胞到發炎處並進一步的破壞骨質。為了更進一步了解其中的調控機制,我們嘗試一種在治療高膽固醇疾病方面的藥物: statin。近年來,statin在治療關節炎方面的確有其療效,但對其治療效果卻有很大的差異。我們利用simvastain藥物以matrigel包裹注射至老鼠膝關節,使之穩定緩慢的釋放出來,發現經由simvastatin治療後,對關節炎的進展有舒緩的效果,證明statin在治療關節炎上極具潛力。另外在in vitro方面,發現simvastatin會經由促進FoxO3a的核轉移(nuclear translocation),使FoxO3a活化後,對下游的Cyr61啟動子進行轉錄抑制,造成Cyr61蛋白表現量的減少。為了更進一步的了解simvastatin是透過何種機制來促進FoxO3a的活性,參考文獻中發現,FoxO3a主要是透過乙醯化(acetylation)及磷酸化(phosphorylation)的方式影響其核轉移,其中乙醯化可能是扮演FoxO3a的重要調控機制之一。另外,我們的研究也指出SIRT在冷光酶分析法(luciferase assay)中可以看到對Cyr61啟動子的抑制,而且SIRT1與FoxO3a蛋白質的交互作用,在共同免疫沉澱法(co-immunoprecipitation)實驗中,的確有結合的現象。顯示出SIRT1在FoxO3a活性的調控中,可能扮演另一個重要的角色。 未來,我們除了在simvastatin所引起下游SIRT1、FoxO3a、Cyr61的分子機制需要更清楚的釐清外。這些蛋白質在膠原蛋白所誘導的關節炎大鼠模式中,也待更進一步的了解其所扮演的地位。希望能夠建立一個完整的研究機制,試圖解釋Simvastatin是透過SIRT1來促進FoxO3a的活性,進而抑制下游基因Cyr61蛋白的表現,使得關節炎中骨頭的骨吸收程度有明顯的緩和作用。利用此完整的機制,對於未來在治療類風濕性關節炎中具有良好的效果。 | zh_TW |
dc.description.abstract | Rheumatoid arthritis is chronic, inflammatory, systemic, autoimmune diseases characterized by chronic arthritis leading to progressive joint erosions. Inflammation recruits immune cells such as macrophage to the site leading to bone erosion. The recruitment of inflammatory cell is the major risk factor in the arthritis and the mechanism is needed more research. Cyr61, the CCN family, named CCN1 has been reported plays an important role in RA patients. Cyr61 mRNA has a significant increase in RA patients and promotes macrophage migration. In our collagen-induced arthritis(CIA) model, Cyr61 expressed and seems to recruit macrophage to bone resorption area means that it may promote macrophage infiltration and resulted in CIA progression. In vitro, treatment of Cyr61 recombinant protein direct promoted macrophage migration and enhanced CCL2 chemokine expression in U2OS. Thus, Cyr61 has the ability to deteriorate RA progression.
Statin, a cholesterol synthesis inhibitor, has been reported to have a potential in therapy of arthritis. To investigate the effect of arthritis, we administrated simvastatin to joint space and led to alleviate CIA progression. By local injection of simvastain, this way of administration can avoid the liver-specific characteristic. In U2OS cell, treatment of simvastatin decreased Cyr61 expression via activation FoxO3a. Simvastatin activated FoxO3a through promoting its nuclear translocation. FoxO3a activity is mediated by post-transcriptional modification that includes phosphorylation and acetylation. Phosphorylation at Thr32, Ser253 and Ser315 leads to nucleus export and acetylation attenuates FoxO3a DNA binding affinity. Simvastain activated FoxO3a through decreasing its phosphorylation and acetylation. Thus, nuclear FoxO3a bound to Cyr61 promoter and repressed transcription. Deacetylation of FoxO3a seems to SIRT1-dependent manner. Treatment of Simvastatin enhanced SIRT1 activity and promoted FoxO3a interaction. The references related to statins on FoxO3a phosphorylation are much clear than acetylation. We found a way that statins mediate FoxO3a acetylation In summary, simvastatin represses Cyr61 expression through promoting FoxO3a deacetylation and nucleus translocation in vitro. In animal model, simvstatin alleviates CIA progression, decreases Cyr61 expression and promotes FoxO3a nuclear translocation that correlated with in vitro data. By confirming the SIRT1/FoxO3a/Cyr61 pathway, it will be a potential target in therapy of RA. | en |
dc.description.provenance | Made available in DSpace on 2021-05-20T20:05:21Z (GMT). No. of bitstreams: 1 ntu-98-R96450006-1.pdf: 4557792 bytes, checksum: dcfddf5c1188d86a724286ceb4951d32 (MD5) Previous issue date: 2009 | en |
dc.description.tableofcontents | 一、目錄
封面 ……………………………………………………… 1 口試記錄表………………………………………… 2 目錄 ……………………………………………………… 3 摘要 ……………………………………………………… 7 -中文摘要 -英文摘要 導論 ………………………………………………… 11 1.1 類風濕性關節炎 (Rheumatoid Arthritis) 1.2 Cyr61與類風濕性關節炎 1.3 Simvastatin與類風溼性關節炎 1.4 FoxO3a與Cyr61 1.5 Sirtuin 與FoxO3a 實驗目的 ……………………………………………… 16 2.1 Simvastatin藉由SIRT1/FoxO3a抑制Cyr61蛋白質表現的機制 2.2 Simvastatin減緩CIA的進展 材料與方法 ……………………………………… 17 3.1 試劑與抗體 3.2 實驗細胞株 3.3 Transient transfection 3.4 細胞內蛋白質的萃取 3.5 西方點墨法 Western blot 3.6 免疫組織染色 3.7 免疫沉澱法 (Immunoprecipitation) 3.8 Collagen induced arthritis in Rat model and simvastatin treat 3.9 染色質免疫沉澱法Chromatin Immunoprecipitation 實驗結果 ………………………………………… 23 4.1 TNF-α誘導Cyr61在成骨細胞的表現 4.2 Simvastatin抑制Cyr61在成骨細胞的蛋白質表現 4.3 Simvastatin藉由FoxO3a調控Cyr61的蛋白質表現 4.4 Simvastatin促進FoxO3a的核轉移 4.5 Simvastatin並促進FoxO3a對Cyr61啟動子的結合親和力 4.6 Simvastatin促進FoxO3a的去乙醯化 4.7 第二型膞原蛋白Type II collagen誘發類風濕性關節炎 4.8 Simvastatin緩和類風溼性關節炎的進展 討論 …………………………………………… 31 5.1 Simvastatin會抑制Cyr61蛋白的表現,且這個過程透過FoxO3a的核轉移機制。 5.2 Simvastatin及Cyr61在collagen induced arthritis Rat中扮演的角色 附件 ……………………………………………………… 37 參考文獻 ………………………………………………… 46 | |
dc.language.iso | zh-TW | |
dc.title | Statin可經由調控成骨細胞Sirtuin/FoxO3a/Cyr61反應途徑來減緩膠原蛋白所誘導之關節炎的發展 | zh_TW |
dc.title | Statin attenuates osteoblastic cell Cyr61 expression via modulating Sirtuin/FoxO3a/Cyr61 signaling pathway: a therapeutic potential for arthritis. | en |
dc.type | Thesis | |
dc.date.schoolyear | 97-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 郭彥彬,蕭宏昇,張正琪 | |
dc.subject.keyword | 關節炎, | zh_TW |
dc.subject.keyword | FoxO3a,Cyr61,Sirtuin, | en |
dc.relation.page | 51 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2009-08-14 | |
dc.contributor.author-college | 牙醫專業學院 | zh_TW |
dc.contributor.author-dept | 口腔生物科學研究所 | zh_TW |
顯示於系所單位: | 口腔生物科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-98-1.pdf | 4.45 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。